Compile Data Set for Download or QSAR
maximum 50k data
Found 72 Enz. Inhib. hit(s) with all data for entry = 8851
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423348(US10501458, Compound 1021)
Affinity DataIC50:  158nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423362(3-methyl-5-{1-[7- (trifluoromethyl)imidazo[1, 5-a]...)
Affinity DataIC50:  251nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423332(US10501458, Compound 1005)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423333(US10501458, Compound 1006)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423334(US10501458, Compound 1007)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423336(US10501458, Compound 1009)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423337(US10501458, Compound 1010)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423339(US10501458, Compound 1012)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423341(US10501458, Compound 1014)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423341(US10501458, Compound 1014)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423343(US10501458, Compound 1016)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423343(US10501458, Compound 1016)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423348(US10501458, Compound 1021)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423348(US10501458, Compound 1021)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423349(US10501458, Compound 1022)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423349(US10501458, Compound 1022)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423350(US10501458, Compound 1023)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423350(US10501458, Compound 1023)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423351(US10501458, Compound 1024)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423351(US10501458, Compound 1024)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423352(US10501458, Compound 1025)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423352(US10501458, Compound 1025)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423353(US10501458, Compound 1026)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423353(US10501458, Compound 1026)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423354(US10501458, Compound 1027)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423355(US10501458, Compound 1028)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423356(US10501458, Compound 1029)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423356(US10501458, Compound 1029)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423357(US10501458, Compound 1030)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423357(US10501458, Compound 1030)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423358(US10501458, Compound 1031)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423358(US10501458, Compound 1031)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423359(US10501458, Compound 1032)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423359(US10501458, Compound 1032)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423360(US10501458, Compound 1033)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423360(US10501458, Compound 1033)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423331(US10501458, Compound 1004)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423327(US10501458, Compound 1002)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423328(US10501458, Compound 1003)
Affinity DataIC50: <300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423363(N,3-dimethyl-5-{1-[7- (trifluoromethyl)imidazo[1, ...)
Affinity DataIC50:  398nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423364(6-amino-1,3-dimethyl-5-{4- [7- (trifluoromethyl)im...)
Affinity DataIC50:  794nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423365(5-[4-(1H-tetrazol-1- yl)piperidin-1-yl]-7- (triflu...)
Affinity DataIC50:  1.00E+3nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423332(US10501458, Compound 1005)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423333(US10501458, Compound 1006)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423337(US10501458, Compound 1010)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423339(US10501458, Compound 1012)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423340(US10501458, Compound 1013)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423340(US10501458, Compound 1013)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIndoleamine 2,3-dioxygenase 1(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423342(US10501458, Compound 1015)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTryptophan 2,3-dioxygenase(Homo sapiens (Human))
Iomet Pharma

US Patent
LigandPNGBDBM423345(US10501458, Compound 1018)
Affinity DataIC50:  1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton™ X100, 20 mM ascorbate, 10 μM methylen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: